Clinical Sessions

EUSOBI Annual Scientific Meeting 2025

September 25–27, 2025
Aberdeen, UK & Online

events.siemens-healthineers.com/eusobi

Innovating Personalized Breast Cancer Diagnostics. For every woman. Everywhere.

We look forward to seeing you at EUSOBI 2025.

In the fight against breast cancer, we have achieved a lot. However, challenges remain: 1 in 8 breast cancers is still missed,[1] 50% of women receiving annual mammograms experience false-positive results,[2] and there is a significant shortage of radiologists and technologists to meet the growing demand for breast cancer screening and diagnosis.[3]

Our ambition is to change that – and to be your partner in delivering a more personalized approach to breast cancer diagnostics. Accurate imaging is essential for effective, individualized treatment.

At this year's European Society of Breast Imaging, we will showcase the latest innovations in breast imaging tailored to each patient's needs:

- Fast, wide-angle DBT enabling 43% increased detection of invasive cancers[4] and significant reduction of interval cancers when introduced in screening[5]
- CEM for significant increased detection of invasive cancers when introduced in BC surveillance[6]
- 40% faster and 2x higher resolution MRI with AI-powered reconstruction[7]
- Better lesion characterization with next-generation 2D SWE and its improved lesion deliniation[8]
- AI solution for significantly reduced reading time in tomosynthesis[5] and 44% reduced reading workload in 2D (compared to double-reading)[9]

Visit our clinical sessions and come to our booth to experience how these latest advancements in breast imaging can support you for faster and more confident treatment decisions.

SIEMENS Healthineers

Siemens Healthineers Clinical Sessions at EUSOBI Annual Scientific Meeting 2025

P&J Live
Aberdeen, United Kingdom

Industry Symposium

Room: Plenum
September, 26
11:00 am – 11:30 am

Please visit our webpage for further session details:

Personalized breast imaging: Cutting-edge strategies for tailored screening and diagnosis

Moderation	Dr. Daan Hellingman *Siemens Healthineers, Den Haag, Netherlands* Dr. Ana Paula Vasconcelos Nunes *Hospital Lusíadas Lisboa, Portugal*
Rethinking breast cancer follow-up: Exploring contrast-enhanced mammography as a game-changer	Dr. Daniela Bernardi *Humanitas University, Milan, Italy*
The role of deep learning in breast MRI	Dr. Heike Preibsch *University of Tübingen, Germany*
Questions & discussion	All

Reading sessions

Room: 1A
September, 25
04:00 pm – 04:45 pm

How I use ultrafast and diffusion breast MRI in clinical practice

Prof. Isabelle Thomassin-Naggara
Hopital Tenon – AP-HP Sorbonne Université, France

Do you want to enhance your skills in using ultrafast and diffusion breast MRI in clinical practice? Join us for an interactive hands-on session and learn how to get the most out of your breast MRI exams. Professor Thomassin-Naggara will take you through some of her most interesting clinical cases and will help you master these MRI techniques.
In this session, you will learn how to:

- Harness the benefits of ultrafast temporal resolution in contrast enhanced scans
- Read and interpret diffusion MRI scans
- Optimize your breast MRI exams for a variety of clinical indications

Room: 1A
September, 26
09:00 am – 09:45 am

The benefits of MRI in women with dense breast – towards personalized breast diagnostics

Dr. Heike Preibsch
University Hospital Tübingen, Germany

Women with dense breast tissue face a higher risk of breast cancer and at the same time a reduced sensitivity of mammography. This hands-on workshop will highlight the role of MRI as a supplemental screening tool in this population, supporting more personalized diagnostic pathways. Through guided review of clinical cases, participants will explore how MRI improves cancer detection, characterizes lesions, and enhances diagnostic confidence. Attendees will interact with real cases on their workstations, gaining practical experience in MRI interpretation for dense breasts.

Precision imaging in breast cancer diagnostics with wide-angle tomosynthesis

Dr. Ruth Walker
University of Southampton, United Kingdom

Digital breast tomosynthesis is now standard. What should change significantly? Experience how DBT can still be improved and how you can benefit from it in breast diagnostics. Dr. Walker is the Director of breast screening at University Hospitals Southampton and has been working with digital breast tomosynthesis for more than 10 years. She will take you through her clinical routine with wide-angle DBT, showcasing a variety of cases from dense breast to micro-calcification, indeterminate lesions and multimodality cases taken from the breast screening service.

Room: 1A
September, 26
10:00 am – 10:45 am
September, 27
08:45 am – 09:30 am

Breast Elastography: Is it a game changer?

Dr. Birgit Amort
University Hospital Innsbruck, Austria

This session will delve into the multifaceted role of breast elastography as a diagnostic tool, emphasizing how advancements in technique and technology significantly impact the diagnostic outcomes for patients. The presentation will provide a concise overview of established protocols and proper technique. By providing additional diagnostic information, elastography reduces the need for invasive biopsies, minimizes patient anxiety, and facilitates earlier and more accurate detection of breast cancer. It also assists in monitoring the response to therapy and detecting recurrences, thus playing a crucial role in patient management and treatment planning.

Room: 1A
September, 26
11:40 am – 12:25 pm
September 27
09:45 am – 10:30 am

The role of contrast-enhanced mammography (CEM) in personalized breast diagnostics: Opportunities and limitations

Dr. Sabine Ohlmeyer
University of Erlangen, Germany

Personalized breast diagnostics are a subject on everyone's lips. Are you considering expanding your comprehensive breast diagnostics to include contrast-enhanced mammography? Take on challenging diagnostic cases with confidence! Discover how next-generation contrast-enhanced mammography can help clarify inconclusive findings from conventional imaging. Join Dr. Ohlmeyer as she shares her clinical experience with the next-gen CEM solution by Siemens Healthineers. Through a compelling series of difficult cases, she will provide expert guidance to help you master this new level imaging technique. This session will also focus on how next-generation contrast-enhanced mammography as an adjunct to mammography can help you localize lesions, address common concerns and demonstrate its impact on patient care.

Room: 1A
September, 26
01:15 pm – 02:00 pm
September, 27
10:45 am – 11:30 am

The Use of AI in Breast Diagnostics: Tools for New Strategies in Reading Management

Prof. Nico Karssemeijer, Henny Rijken MSc
Radboud University / Screenpoint Medical, Nijmegen, Netherlands

Reading mammograms is complex, even for experienced radiologists. With the rapid rise of AI tools, it's easy to feel overwhelmed by the options. But how do these systems actually work with 2D and 3D mammography in real clinical practice? In this interactive session, we'll take a deep dive into how AI can streamline and strengthen your screening and diagnostic workflow. Through real-world clinical cases, you'll see how Transpara® Breast AI supports radiologists by identifying suspicious findings, comparing priors, and assessing risk.

Room: 1A
September, 26
03:25 pm – 04:10 pm
September, 27
01:15 pm – 02:00 pm

Please visit our webpage for further session details:

At Siemens Healthineers, we pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably. As a market leader, we want to advance a world in which breakthroughs in healthcare create new possibilities with a minimal impact on our planet. We've been pushing the boundaries in medical technology for more than 125 years. By consistently bringing innovations to the market, we enable healthcare professionals to innovate personalized care, achieve operational excellence, and transform the system of care.

With the unique combination of our strengths in patient twinning,[1] precision therapy, as well as digital, data, and artificial intelligence (AI), we are well positioned to take on the greatest challenges in healthcare. We will continue to build on these strengths to help overcome the world's most threatening diseases, enable efficient operations, and expand access to care.

Our portfolio, spanning in vitro and in vivo diagnostics to image-guided therapy and cancer care, is crucial for clinical decision-making and treatment pathways. We are committed to improving healthcare access for all, limiting our environmental impact as we pioneer breakthroughs, and engaging our diverse Healthineers to achieve this impact on a global scale.

Motivated by our purpose and guided by our values, we are building an inclusive culture, where we embrace diversity in all its forms. We are a team of more than 73,000 Healthineers in over 70 countries passionately pushing the boundaries of what is possible in healthcare to help improve the lives of people around the world.

[1] *Personalization of diagnosis, therapy selection and monitoring, aftercare, and managing health.*

[1] *Ekpo EU, et al. (2018): Errors in Mammography Cannot be Solved Through Technology Alone.*

[2] *American Cancer Society (2022): Limitations of Mammograms. https://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/mammograms/limitations-of-mammograms.html*

[3] *Advanced Health Education Center (2021): Radiology Staffing Shortages Nation Wide? https://aheconline.blog/2021/09/27/radiology-staffing-shortages-nation-wide/*

[4] *Compared to FFDM; Zackrisson S, Lång K, Rosso A, et al. (2018) One-view breast tomosynthesis versus two-view mammography in the Malmö Breast Tomosynthesis Screening Trial (MBTST): A prospective, population-based, diagnostic accuracy study*

[5] *Vilmun BM, Napolitano G, Lillholm M, et al. Introduction of one-view tomosynthesis in population-based mammography screening: Impact on detection rate, interval cancer rate and false-positive rate. Journal of Medical Screening. 2024;32(1):28-34. doi:10.1177/09691413241262259*

[6] *https://events.siemens-healthineers.com/sessions/symposium/rethinking-breast-cancer-follow-up*

[7] *Data on file*

[8] *Barr RG, Engel A, Kim S, et al. Improved Breast 2D SWE Algorithm to Eliminate False Negative Cases. Investigative Radiology. 2023*

[9] *van Winkel et al. Impact of artificial intelligence support on accuracy and reading time in breast tomosynthesis image interpretation. Eur Radiol. 2021;31:8682-8691; 6 https://www.thelancet.com/journals/landig/article/PIIS2589-7500(24)00267-X/fulltext; Next-Gen AI is an option and available with Transpara® (FusionAI™ ScreenPointMedical)*

Siemens Healthineers
EUSOBI Website

Siemens Healthineers Headquarters
Siemens Healthineers AG
Siemensstr. 3
91301 Forchheim, Germany
Phone: +49 9191 18-0
siemens-healthineers.com

Published by Siemens Healthineers AG · A91XP-50010-31C-2-7600 ·